Can artificial intelligence and machine learning (AIML) be used to support portfolio decision-making across the life sciences industry?
In this installment of our Industry Impact Series, we find that not only can the latest AIML techniques identify the drivers of success and failure in commercialization, but Trinity Life Sciences’ AI algorithm accurately predicts revenue outcomes for >90% of U.S. drug launches, far exceeding the accuracy of Wall Street analyst consensus at the time of launch (<60%).
Trinity’s AI algorithm incorporates publicly available and Trinity-proprietary data from our Annual Drug Index on 250+ U.S. drug launches since 2014. Read our white paper, Predicting Winners: AI-Powered Portfolio Management, to learn more.
In Case You Missed It
Complete the form below to access the full white paper
By clicking "I agree" above, you are agreeing that Trinity will use and protect your personal data in accordance with our Privacy Policy. You can opt out of future marketing communications at any time by clicking the unsubscribe link at the bottom of any marketing email you receive from Trinity.